Interaction Checker

Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

New primary drug, HCV DAA Ravidsavir

Thursday 31 August 2023

We have added Ravidasvir (Ravida®) to the drug interaction checker, in our first addition to the lineup of Direct Acting Antivirals for many years. 

Ravidasvir is an NS5A inhibitor approved for use with sofosbuvir, which achieved a 97% cure rate in clinical trials in Malaysia. Ravidasvir is an affordable medication, that will expand access to an HCV cure to low-to-middle-income countries. Ravidasvir does not interact with CYP enzymes but is a P-gp substrate, so coadministration with strong P-gp inducers is contraindicated and coadministration with moderate P-gp inducers is not recommended.

Our thanks to DNDi for providing pharmacokinetic data to assist with writing the drug interactions.

Awards and commendations
bma-foundation-for-medical-research british-medical-journal-2018 queens_aniversary_prize_2017 rcp-excellence-patient-care-awards-2017 building_better_healthcare_awards_2016